AI drug development startup Pathos AI closes $237M investment
SiliconANGLE
Read the full article
Pathos AI raised $237M at a $3B valuation to advance its AI-driven cancer drug development platform, Foundry, which analyzes vast oncological data to identify promising drug candidates and plan biomarker-driven clinical trials.
